Evidence map›Paper›PMID 28073872›Full record

ReviewBMJ case reports2017

Gambling disorder: a side effect of an off-label prescription of baclofen-literature review.

Morgane Guillou-Landreat, Caroline Victorri Vigneau, Marie Gerardin

Abstract readCase ReportsReview
In one paragraph

Review in BMJ case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Morgane Guillou-LandreatERCR SPURBO, Department of Addictive Disorders, Université de Bretagne Occidentale, Brest, France.
Caroline Victorri VigneauClinical Pharmacology, CHU Nantes, Nantes, Pays de la Loire, France.
Marie GerardinClinical Pharmacology, CHU Nantes, Nantes, Pays de la Loire, France.
Centre d'Investigation Clinique de Nantes · FRUniversité de Bretagne Occidentale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of high-dose baclofen emerged in 2008 in the treatment of alcohol-use disorders. Its prescription is still off-label in France, but recent trials have suggested the interest of using high doses for alcohol dependence, so we have to deal with an increase in its use. However, we still have few data about the adverse effects of a high-dose baclofen prescription, especially in complex addictive disorders. We present a case of a 32-year-old man who sought treatment for gambling disorders (GDs). He had complex addictive disorders, including alcohol-use disorders and GDs. He developed a severe GD, after treatment with a high dose of baclofen. The maximum dose was 160 mg/day, prescribed for his alcohol-use disorders. According to the Naranjo algorithm, the score was +7, it enabled to conclude that problem of gambling was probably imputable to baclofen. We discuss this case with reference to literature.

Indexed as

AdultAlcohol DeterrentsAlcohol-Related DisordersBaclofenDiagnosis, DifferentialGABA-B Receptor AgonistsGamblingHumansMaleOff-Label UseTreatment OutcomeAlcohol DeterrentsBaclofenGABA-B Receptor Agonists

Identifiers

PMID28073872
PMCPMC5256589
OpenAlexW2568340713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.